 xxxd1976xxx  pfizer.  pfizer has developed and launched  xxxd1976xxx , a 5-ht1b/1d agonist, for the potential treatment of migraine with and without aura.  xxxd1976xxx  has 6-fold greater affinity for the  xxxg1110xxx  receptor than sumatriptan, and a 3-fold greater affinity for the  xxxg1109xxx  [249570].  xxxd1976xxx  pharmacology has also been evaluated in vitro in comparison with  xxxd3562xxx  (astrazeneca plc) and naratriptan (glaxosmithkline plc) [290116].